<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zarei M</submitter><funding>Hormozgan University of Medical Sciences</funding><pagination>e1826</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10172159</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Breast cancer is considered the most prevalent type of cancer in women and accounts for a high rate of death. A body of research has demonstrated that lncRNAs have a regulatory function in human diseases, especially cancers. ZEB2-AS1 is known as an oncogenic lncRNA in various types of cancers, and its deregulation may contribute to cancer development and progression. Therefore, we aimed to reveal the association of ZEB2-AS1 expression with epithelial-mesenchymal transition (EMT) markers, as a hallmark of cancer progression, in a clinical setting.&lt;h4>Methods&lt;/h4>A recent study suggested that ZEB2-AS1 is significantly involved in EMT. Here we intended to explore the roles of lncRNA ZEB2-AS1 in breast cancer (BC) using bioinformatics tools and laboratory settings. We first </pubmed_abstract><journal>Cancer reports (Hoboken, N.J.)</journal><pubmed_title>Clinical significance of long non-coding RNA ZEB2-AS1 and EMT-related markers in ductal and lobular breast cancer.</pubmed_title><pmcid>PMC10172159</pmcid><funding_grant_id>980059</funding_grant_id><pubmed_authors>Zarei M</pubmed_authors><pubmed_authors>Malekzadeh K</pubmed_authors><pubmed_authors>Mousavi P</pubmed_authors><pubmed_authors>Omidi M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical significance of long non-coding RNA ZEB2-AS1 and EMT-related markers in ductal and lobular breast cancer.</name><description>&lt;h4>Background&lt;/h4>Breast cancer is considered the most prevalent type of cancer in women and accounts for a high rate of death. A body of research has demonstrated that lncRNAs have a regulatory function in human diseases, especially cancers. ZEB2-AS1 is known as an oncogenic lncRNA in various types of cancers, and its deregulation may contribute to cancer development and progression. Therefore, we aimed to reveal the association of ZEB2-AS1 expression with epithelial-mesenchymal transition (EMT) markers, as a hallmark of cancer progression, in a clinical setting.&lt;h4>Methods&lt;/h4>A recent study suggested that ZEB2-AS1 is significantly involved in EMT. Here we intended to explore the roles of lncRNA ZEB2-AS1 in breast cancer (BC) using bioinformatics tools and laboratory settings. We first </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-04T10:19:22.549Z</modification><creation>2025-02-19T00:12:15.504Z</creation></dates><accession>S-EPMC10172159</accession><cross_references><pubmed>37088469</pubmed><doi>10.1002/cnr2.1826</doi></cross_references></HashMap>